Showing results (31-40 of 52) with videos related to
Sort By:
Pageof 6
CNS Drugs|March 5, 2017
Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial DataMats O Magnusson, Mahesh N Samtani, Elodie L Plan, et al.Clinical Pharmacokinetics|October 16, 2016
Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with SchizophreniaMats O Magnusson, Mahesh N Samtani, Elodie L Plan, et al.BMC Psychiatry|March 30, 2012
A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophreniaDanielle Coppola, Yanning Liu, Srihari Gopal, et al.Journal of Clinical Pharmacology|July 21, 2015
Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label studyPaulien Ravenstijn, Bart Remmerie, Adam Savitz, et al.Journal of Alzheimer'S Disease : JAD|June 23, 2011
Quantifying the pathophysiological timeline of Alzheimer's diseaseEric Yang, Michael Farnum, Victor Lobanov, et al.British Journal of Clinical Pharmacology|April 27, 2012
Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypesMahesh N Samtani, Nandini Raghavan, Yingqi Shi, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 11, 2025
Efficacy, safety, and tolerability of JNJ-61393215 (tebideutorexant), a selective orexin-1 receptor antagonist, as adjunctive treatment for major depressive disorder with anxious distress: A double-blind, placebo-controlled, randomized phase 2a studyMark E Schmidt, John A Moyer, Iva Kezic, et al.Current Medical Research and Opinion|August 27, 2015
Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophreniaSrihari Gopal, An Vermeulen, Partha Nandy, et al.European Journal of Drug Metabolism and Pharmacokinetics|May 15, 2024
Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I)Huybrecht T'jollyn, Alberto Russu, Raja Venkatasubramanian, et al.Journal of Alzheimer'S Disease : JAD|May 23, 2012
A novel subject synchronization clinical trial design for Alzheimer's diseaseTimothy Schultz, Eric Yang, Michael Farnum, et al.Pageof 6